Siderocalin fusion proteins enable a new 86Y/90Y theranostic approach

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The mammalian protein siderocalin binds bacterial siderophores and their iron complexes through cation-π and electrostatic interactions, but also displays high affinity for hydroxypyridinone complexes of trivalent lanthanides and actinides. In order to circumvent synthetic challenges, the use of siderocalin-antibody fusion proteins is explored herein as an alternative targeting approach for precision delivery of trivalent radiometals. We demonstrate the viability of this approach in vivo, using the theranostic pair 90Y (β−, t1/2 = 64 h)/86Y (β+, t1/2 = 14.7 h) in a SKOV-3 xenograft mouse model. Ligand radiolabeling with octadentate hydroxypyridinonate 3,4,3-LI(1,2-HOPO) and subsequent protein binding were achieved at room temperature. The results reported here suggest that the rapid non-covalent binding interaction between siderocalin fusion proteins and the negatively charged Y(iii)-3,4,3-LI(1,2-HOPO) complexes could enable purification-free, cold-kit labeling strategies for the application of therapeutically relevant radiometals in the clinic.

Cite

CITATION STYLE

APA

Cosby, A. G., Arino, T., Bailey, T. A., Buerger, M., Woods, J. J., Aguirre Quintana, L. M., … Abergel, R. J. (2023). Siderocalin fusion proteins enable a new 86Y/90Y theranostic approach. RSC Chemical Biology, 4(8), 587–591. https://doi.org/10.1039/d3cb00050h

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free